Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- 53
Summary
- Conditions
- Epigallocatechin Gallate
- Esophagitis
- Lung Neoplasms
- Prevention & Control
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Participant)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02577393
- Collaborators
- Not Provided
- Investigators
- Study Chair: Ligang Xing, MD,PhD Shandong Cancer Hospital and Institute